Holen Sie sich die Stockscreener-App
1.32
1.54%
0.02
Handel nachbörslich:
1.34
0.02
+1.52%
Schlusskurs vom Vortag:
$1.30
Offen:
$1.2
24-Stunden-Volumen:
73,974
Relative Volume:
5.56
Marktkapitalisierung:
$47.76M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-41.36M
KGV:
-0.8049
EPS:
-1.64
Netto-Cashflow:
$-42.09M
1W Leistung:
-20.00%
1M Leistung:
-33.67%
6M Leistung:
-42.61%
1J Leistung:
-63.84%
1-Tages-Spanne:
$1.15
$1.34
1-Wochen-Bereich:
$1.15
$1.8114
52-Wochen-Spanne:
$1.15
$3.85
Armata Pharmaceuticals Inc Stock (ARMP) Company Profile
Firmenname
Armata Pharmaceuticals Inc
Sektor
Branche
Telefon
310-655-2928
Adresse
4503 Glencoe Avenue, Marina del Rey, CA
Vergleichen Sie ARMP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARMP
Armata Pharmaceuticals Inc
|
1.32 | 47.76M | 0 | -41.36M | -42.09M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Armata Pharmaceuticals Inc Stock (ARMP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2019-06-19 | Eingeleitet | Ladenburg Thalmann | Buy |
Armata Pharmaceuticals Inc Aktie (ARMP) Neueste Nachrichten
Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Expands By 28.3% - Defense World
Bacteriophage Therapy Market Future Business Opportunities - openPR
HC Wainwright Comments on Armata Pharmaceuticals Q1 Earnings - Defense World
Armata Pharmaceuticals Inc (ARMP) Q4 2024 Earnings: EPS of $0.07 - GuruFocus
Armata Pharmaceuticals reports Q4 EPS (23c) vs (55c) last year - MSN
Armata Pharmaceuticals Inc. (ARMP) reports earnings - Quartz
Armata Pharmaceuticals Announces Fourth Quarter And Full-Year 2024 Results And Provides Corporate Update - MarketScreener
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update - Nasdaq
Armata Pharmaceuticals (ARMP) Projected to Post Quarterly Earnings on Thursday - Defense World
Armata Pharmaceuticals secures $10 million credit By Investing.com - Investing.com Australia
Armata Pharmaceuticals secures $10 million credit - Investing.com India
Armata Pharmaceuticals Secures $10M Loan for Clinical Trials - TipRanks
Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva - Eastern Progress
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit - Quantisnow
Non-Cystic Fibrosis Bronchiectasis Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight - The Globe and Mail
10 Best Healthcare Stocks to Invest In (March 2025) - Securities.io
Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Rises By 7.5% - MarketBeat
Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Grows By 203.3% - MarketBeat
Chronic Pulmonary Infections Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Teva Pharma, Merck, F. Hoffmann-La Roche, Novartis, GlaxoSmithKline, AstraZeneca - The Globe and Mail
Phage Therapies Clinical Trial Pipeline Shows Potential with Active Contributions from 20+ Key Companies | DelveInsight - GlobeNewswire Inc.
Phage Therapies Clinical Trial Pipeline Shows Potential - GlobeNewswire
Armata Pharmaceuticals (STU:TG1N) PS Ratio : (As of Jan. 14, 2025) - GuruFocus.com
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Update - MarketBeat
Armata Pharmaceuticals Announces $35 Million Secured Credit Agre - GuruFocus.com
Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Grows By 125.9% - MarketBeat
Ampliphi Biosciences (NYSEAMERICAN:APHB) Announces Positive Results from Phase 2 Tailwind Study - Defense World
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Earns “Buy” Rating from HC Wainwright - Defense World
Armata Pharma’s inhaled AP-PA02 shows positive results in Phase 2 study - Yahoo Finance
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Given Buy Rating at HC Wainwright - MarketBeat
Armata Pharmaceuticals Reports Positive Phase 2 Study Results - TipRanks
Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection - PR Newswire
ARMP Stock Touches 52-Week Low at $1.98 Amid Market Challenges - Investing.com
Suparna Mishra Sarkar - Los Angeles Times
Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia - The Eastern Progress Online
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting - The Eastern Progress Online
Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer - The Eastern Progress Online
Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit - GuruFocus.com
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 - Marketscreener.com
Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update - GuruFocus.com
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Tops Revenue Estimates - MSN
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting – Company AnnouncementFT.com - Financial Times
Armata Pharmaceuticals FY2024 EPS Raised by HC Wainwright - MarketBeat
Armata Pharmaceuticals Extends Credit Agreement and CMO Departs - TipRanks
HC Wainwright Reiterates “Buy” Rating for Armata Pharmaceuticals (NYSEAMERICAN:ARMP) - Defense World
Armata Pharmaceuticals Reports $3M Revenue, Advances Key Clinical Trials in Q3 | ARMP Stock News - StockTitan
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Given "Buy" Rating at HC Wainwright - MarketBeat
Finanzdaten der Armata Pharmaceuticals Inc-Aktie (ARMP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):